We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Long-term drug survival of adalimumab, infliximab, secukinumab and ustekinumab in hidradenitis suppurativa: a Danish nationwide cohort study.
- Authors
Ring, Hans Christian; Thorsen, Jonathan; Kirby, Brian; Ingram, John R; Rosenø, Nana Aviaaja Lippert; Holgersen, Nikolaj; Nielsen, Valdemar W; Aagaard, David Nikolai Thein; Maul, Julia-Tatjana; Wu, Jashin J; Thyssen, Jacob P; Egeberg, Alexander; Thomsen, Simon F
- Abstract
This article presents a Danish nationwide cohort study on the long-term drug survival of biologics in the treatment of hidradenitis suppurativa (HS), a chronic inflammatory skin disease. The study analyzed data from 452 patients who were treated with various biologics between 2005 and 2021. The results showed that the median drug survival time for adalimumab was approximately 8 months, with bio-naïve patients having a significantly longer drug survival time compared to non-naïve patients. The study also reported real-life drug survival data on secukinumab in HS. The findings suggest the need for further research into more effective biologics for HS.
- Subjects
HIDRADENITIS suppurativa; ADALIMUMAB; INFLIXIMAB; COHORT analysis; BIOTHERAPY; DRUGS
- Publication
British Journal of Dermatology, 2024, Vol 190, Issue 5, p769
- ISSN
0007-0963
- Publication type
Article
- DOI
10.1093/bjd/ljae042